Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (7603)	5/5/1999 7:54:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

MKilloran <<Nausia, vomiting side effects in up to 16% of the patients......>> MK: Welcome back to the PFEr Board! I agree. If approved in 2000, Uprima will only be a minor product in the ED market...probably reserved for Viagra failures. Max peak annual sales $100- $150 million. BigKNY3

To: Mkilloran who wrote (7603)	5/5/1999 8:27:00 PM
From: Brander	Read Replies (2) \| Respond to of 9523

You state "Nausia, vomiting side effects in up to 16% of the patients" The pr reports Nausea in 0.5 to 16% of the patients. It says nothing about vomiting, and I would guess the percentage of vomiting is much lower. They are two different things, with nausea being much more common than vomiting. In addition, 0.5 to 16% rate of nausea is the same rate seen in some of the more popular antidepressants, and it does not inhibit their use much. If this medication from Uprima is effective, it will be popular. From the data I have seen to date, the effectiveness rate is less than that for Viagra.